Two_CD
distinct_JJ
signal_NN
transmission_NN
pathways_NNS
in_IN
T_NN
lymphocytes_NNS
are_VBP
inhibited_VBN
by_IN
complexes_NNS
formed_VBN
between_IN
an_DT
immunophilin_NN
and_CC
either_CC
FK506_NN
or_CC
rapamycin_NN
._.

Proliferation_NN
and_CC
immunologic_JJ
function_NN
of_IN
T_NN
lymphocytes_NNS
are_VBP
initiated_VBN
by_IN
signals_NNS
from_IN
the_DT
antigen_NN
receptor_NN
that_WDT
are_VBP
inhibited_VBN
by_IN
the_DT
immunosuppressant_JJ
FK506_NN
but_CC
not_RB
by_IN
its_PRP$
structural_JJ
analog_NN
,_,
rapamycin_NN
._.

On_IN
the_DT
other_JJ
hand_NN
,_,
interleukin_NN
2_CD
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
-_:
induced_VBN
signals_NNS
are_VBP
blocked_VBN
by_IN
rapamycin_NN
but_CC
not_RB
by_IN
FK506_NN
._.

Remarkably_RB
,_,
these_DT
two_CD
drugs_NNS
inhibit_VBP
each_DT
other_JJ
's_POS
actions_NNS
,_,
raising_VBG
the_DT
possibility_NN
that_IN
both_DT
act_VBP
by_IN
means_NNS
of_IN
a_DT
common_JJ
immunophilin_NN
-LRB-_-LRB-
immunosuppressant_JJ
binding_NN
protein_NN
-RRB-_-RRB-
._.

We_PRP
find_VBP
that_IN
the_DT
dissociation_NN
constant_NN
of_IN
rapamycin_NN
to_TO
the_DT
FK506_NN
binding_NN
protein_NN
FKBP_NN
-LRB-_-LRB-
Kd_NN
=_JJ
0.2_CD
nM_NN
-RRB-_-RRB-
is_VBZ
close_JJ
to_TO
the_DT
dissociation_NN
constant_NN
of_IN
FK506_NN
to_TO
FKBP_NN
-LRB-_-LRB-
Kd_NN
=_JJ
0.4_CD
nM_NN
-RRB-_-RRB-
and_CC
to_TO
their_PRP$
effective_JJ
biologic_JJ
inhibitory_JJ
concentrations_NNS
._.

However_RB
,_,
an_DT
excess_NN
of_IN
rapamycin_NN
is_VBZ
needed_VBN
to_TO
revert_VB
FK506-mediated_JJ
inhibition_NN
of_IN
IL-2_NN
production_NN
,_,
apoptosis_NN
,_,
and_CC
transcriptional_JJ
activation_NN
of_IN
NF-AT_NN
,_,
a_DT
T-cell-specific_JJ
transcription_NN
factor_NN
necessary_JJ
for_IN
IL-2_NN
gene_NN
activation_NN
._.

Similarly_RB
,_,
an_DT
excess_NN
of_IN
FK506_NN
is_VBZ
needed_VBN
to_TO
revert_VB
rapamycin-mediated_JJ
inhibition_NN
of_IN
IL-2-induced_JJ
proliferation_NN
._.

The_DT
drug_NN
concentrations_NNS
required_VBN
for_IN
antagonism_NN
may_MD
be_VB
explained_VBN
by_IN
the_DT
relative_JJ
affinity_NN
of_IN
the_DT
drugs_NNS
to_TO
,_,
and_CC
by_IN
the_DT
abundance_NN
of_IN
,_,
the_DT
immunophilin_NN
FKBP_NN
._.

FKBP_NN
has_VBZ
been_VBN
shown_VBN
to_TO
catalyze_VB
the_DT
interconversion_NN
of_IN
the_DT
cis_NN
-_:
and_CC
trans-rotamers_NNS
of_IN
the_DT
peptidyl-prolyl_JJ
amide_NN
bond_NN
of_IN
peptide_NN
substrates_NNS
;_:
here_RB
we_PRP
show_VBP
that_IN
rapamycin_NN
,_,
like_IN
FK506_NN
,_,
is_VBZ
a_DT
potent_JJ
inhibitor_NN
of_IN
the_DT
rotamase_NN
activity_NN
of_IN
FKBP_NN
-LRB-_-LRB-
Ki_NN
=_JJ
0.2_CD
nM_NN
-RRB-_-RRB-
._.

Neither_CC
FKBP_NN
binding_NN
nor_CC
inhibition_NN
of_IN
rotamase_NN
activity_NN
of_IN
FKBP_NN
alone_RB
is_VBZ
sufficient_JJ
to_TO
explain_VB
the_DT
biologic_JJ
actions_NNS
of_IN
these_DT
drugs_NNS
._.

Rather_RB
,_,
these_DT
findings_NNS
suggest_VBP
that_IN
immunophilin_NN
bound_VBN
to_TO
FK506_NN
interferes_VBZ
with_IN
antigen_NN
receptor-induced_JJ
signals_NNS
,_,
while_IN
rapamycin_NN
bound_VBN
to_TO
the_DT
immunophilin_NN
interferes_VBZ
with_IN
IL-2-induced_JJ
signals_NNS
._.

